- 01CostCost per treatment, not revenueThe variable product cost — what leaves your inventory every time you perform the service. For injectables it is knowable to the unit.
- 02MarginContribution margin, per service linePrice minus product cost: the money each treatment leaves behind to cover rent, payroll and the medical director. Separately per line — they do not behave alike.
- 03Break-evenFixed opex ÷ blended contribution marginOnly now does break-even have a meaning. Fixed opex is everything you owe whether or not a single patient books.
Templates hand you a market-size paragraph and a promise that you will break even in three to nine months. No dataset supports that number, because break-even is not a fact about the industry — it is a fact about your fixed costs and your margins. It comes out of these three steps, in this order.
What every template gets right — and where they stop
Give the standard med spa business plan its due. The outline is genuinely useful and you should write all of it:
- Executive summary, market analysis, and services — what you offer and to whom.
- Ownership, staffing, and the medical director — the compliance backbone of an aesthetic practice.
- Marketing and operations — how patients find you and what happens when they arrive.
- A startup-cost range — usually a single band like "$200K–$500K."
Where they stop is usually the same place. They give you a cost range and a break-even timeline, and they call that the financial plan. But a range isn't a model, and a timeline isn't a calculation — it's a guess someone else made about a business that isn't yours. What's missing is the arithmetic that connects the two: the cost of one Botox appointment, the margin left after product, and the monthly revenue that actually covers your fixed costs. That arithmetic is below.
The market numbers — and which ones are real
Start with an honest read of the industry, because this is where the exaggeration begins. The measured numbers — from the American Med Spa Association's own State of the Industry summary — look like this:
Those are real, published averages, and they're the ones to build a plan against. The trouble starts when the bigger, rounder numbers get borrowed as if they mean the same thing.
None of this makes the opportunity smaller — the count grew by more than 1,500 spas in a single year and 18% of them were brand-new in 2023. It just means your plan should anchor on the surveyed $1.4M and $527, remembering that AmSpa builds these figures by marrying its survey to public data rather than counting alone, not on a headline that quietly changed the subject.
The numbers section templates skip: your unit economics
Here's the part most templates skip. A med spa isn't one business — it's four or five little ones stacked together, each with completely different economics. You can't plan it with a single "margin %." You have to start at the level of a single treatment.
Step one: cost per treatment, not revenue
Before you can price anything, you need the variable product cost — what leaves your inventory every time you perform the service. For injectables that number is knowable:
- Neurotoxin (Botox and friends). AbbVie's public list price (WAC) is about $656 per 100-unit vial — roughly $6.56 a unit. In practice, low-volume providers pay $500–$600 a vial and high-volume chains negotiate toward $300–$400, so your real cost lands around $4–$6 per unit. A 20-unit glabellar treatment is therefore about $80–$120 in product, plus reconstitution supplies and injector time.
- Dermal filler. Wholesale runs somewhere around $250–$400 per syringe by common report, and I could not trace that range to a document I would call a source, so treat this row as the softest in the table (approximate and brand-dependent), against a retail price that usually runs $600–$1,200 — around $750 on average. Higher revenue per appointment than neurotoxin, but a lower margin and a longer repeat cycle — 6–12 months versus 3–4 for a toxin.
- Laser and energy devices. Once the machine is paid off, the marginal product cost is close to zero — the highest incremental margin in the building. The catch is that the device itself is a large fixed cost you carry whether or not it's booked.
- Retail skincare. A straightforward wholesale-to-retail markup, minimal clinical time — low margin percentage, but almost no cost to deliver.
Every one of those product-cost figures is a range on purpose. Your negotiated pricing, your local retail rates, and your volume will move them. That's exactly why a plan needs your inputs, not a borrowed benchmark.
Step two: contribution margin, per service line
Now subtract product cost from price and you get contribution margin — the money each treatment leaves behind to cover rent, payroll and the medical director. Do it separately for each line, because they don't behave alike:
| Service line | Typical patient price | Product cost | What to notice |
|---|---|---|---|
| Neurotoxin (~20u) | $240–$400 | $80–$120 | Strong margin, short 3–4 month repeat cycle — your frequency engine |
| Dermal filler (1 syringe) | $600–$1,200 | $250–$400 | Higher ticket, lower margin %, longer 6–12 month repeat |
| Laser / energy | $200–$600+ | ~$0 marginal | Highest incremental margin — but the device is a fixed cost |
| Retail skincare | varies | wholesale cost | Low clinical time; a margin cushion, not a headline |
Illustrative, using public list and wholesale prices — your negotiated costs and local pricing will differ. Prices exclude injector time and overhead, which contribution margin is meant to cover.
The lesson of the table is the whole point of the section: a plan that folds neurotoxin, filler, lasers and retail into one blended margin is hiding the thing that determines whether it works. A toxin-led spa and a device-led spa are different companies with different break-evens.
Break-even is a formula, not a promise
Templates love to promise you'll break even in as little as 3–9 months — a number no dataset supports, because break-even isn't a fact about the industry. It's a fact about your fixed costs and your margins, and it comes out of one equation:
Fixed opex is everything you owe whether or not a single patient books — and it's where the med-spa-specific line most templates forget lives:
- Rent — commonly quoted at $3,000–$7,000 a month, higher in dense metros. That band is trade convention, not a figure I can source; get a real quote for your postcode before it goes in a plan.
- Base payroll — front desk, an aesthetician, an injector's base.
- Medical director retainer — roughly $1,000–$5,000 a month ($12,000–$60,000 a year). In most states an aesthetic practice needs supervising-physician oversight, and in full practice authority states a nurse practitioner may own and run one without it, and generic business-plan templates leave this line out entirely.
- Software, insurance, and a marketing baseline — the steady spend to keep the lights on and the calendar full.
Put numbers to it. Say your fixed opex lands near $30,000 a month and your blended contribution margin — weighted across your mix — is about 70%. Then break-even revenue is $30,000 ÷ 0.70 ≈ $42,900 a month, which at the $527 average visit is roughly 81 visits a month — well under the ~245 an established location averages, but a real hill to climb from a standing start. Change the inputs and the answer moves; that's the point. Plan on being cash-flow negative for the first several months and recouping your capex over two to four years, but compute your own version instead of trusting a promised date. (The $30K and 70% here are placeholders to show the arithmetic — replace them with your quotes.)
The line every plan gets wrong: prepaid memberships
Memberships and prepaid packages are the med spa's best friend and a common, costly accounting mistake. On the upside, recurring plans smooth out revenue and pull clients back — and retention matters here more than almost anywhere, given that repeat clients are already 73% of the average spa's visits. Consultants estimate memberships can reach 20–30% of a mature spa's revenue; treat that as an informed target rather than a measured fact, but the direction is right.
Here's the trap. Prepaid money is a liability, not revenue — until you deliver the treatment. When a client buys a $1,200 package, that isn't $1,200 of revenue this month; it's $1,200 of obligation you'll recognize a slice at a time as she redeems visits. Book it all as earned on the day it's sold and a strong sales month looks wildly profitable, your margins look better than they are, and you spend against cash you still owe in services. Getting this one line right — deferred revenue recognized on delivery — is what separates a plan that survives contact with reality from one that flatters you until the packages come due. There's more to it than one line, though: an unlimited membership and a prepaid package are recognized on two different revenue models, and only one of them ever produces breakage.
From plan targets to the numbers you'll track
Everything above is target-setting: the margins you intend to hold, the visits you need, the membership mix you're aiming for. The moment you open, those targets become questions you have to answer with real data — and that's a different job from writing the plan.
Two of these are worth planning for specifically because they leak the most money quietly: an empty chair earns nothing, so a rising no-show rate erases margin you already budgeted, and slipping retention quietly raises what you must spend to fill the calendar. Write targets for both into the plan, then watch them from day one.
Frequently asked questions
There's no single number, because equipment is the swing factor. Vendor-consultant estimates cluster around $150,000–$250,000 for a lean, injectables-first spa and $300,000–$500,000 or more once you add energy devices — which is a band as wide as the ones I complained about at the top, and that is the point: no range substitutes for itemising. The honest way to plan it is to itemize: buildout, devices (often 40–50% of capex), initial neurotoxin and filler inventory, licensing and HIPAA setup, and a working-capital reserve to cover roughly six cash-flow-negative months. These are consultant consensus ranges, not a measured dataset, so treat them as a starting point and price your own build.
The American Med Spa Association's most recent measured average annual revenue per location was about $1,398,833 (its 2024 State of the Industry recap, year-end 2023 data), with patients spending an average of $527 per visit and a location seeing around 245 patient visits a month. Those three do not multiply back: 245 × $527 × 12 is about $1.55M, roughly 11% above the $1.4M average. They come from different questions in the same survey, which is exactly why you plan from your own numbers rather than from a set of national ones. You'll also see a $2 million average quoted — that isn't a fabrication, it is AmSpa's own projection from an earlier report cycle, about $1.98 million forecast for 2022 before that year was surveyed. When AmSpa did survey it, the figure came in at $1.31 million, and its recap puts year-end 2023 at $1.40 million. Anchor on the surveyed $1.4 million and treat the older $2 million as superseded, not a benchmark to expect.
There's no profit or EBITDA figure in AmSpa's free materials. A 27.6% EBITDA figure (for a single-location spa around $1.5 million) is widely attributed to AmSpa's paid State of the Industry report, but it can't be independently verified outside the paywall, and the round 20–25% net margin you'll see everywhere is a consultant heuristic, not a measured benchmark. Your margin is driven almost entirely by service mix: lasers and energy devices carry the highest margin once the device is paid off, injectables sit in the middle, and retail skincare is lowest. Model it per service line rather than assuming one blended percentage.
Break-even isn't a fixed timeline you can look up — templates promise as little as 3–9 months, but no dataset supports any fixed timeline. It's a formula: break-even monthly revenue = fixed monthly operating costs ÷ your blended contribution margin percentage. Add up your fixed costs (rent, base payroll, the medical-director retainer, software, insurance, baseline marketing), estimate the average margin left after product cost across your service mix, and divide. Then compare that revenue to your ramp to see how many months it really takes.
No — not when the money arrives. A prepaid package or membership is deferred revenue, a liability you owe in future treatments, and you recognize it as revenue only as clients redeem it. Selling a $1,200 package isn't $1,200 of revenue this month; it's $1,200 of obligation. Counting prepayments as earned revenue is a common and costly accounting mistake in med spa plans, and it makes a strong sales month look far more profitable than it is.
WRITTEN BY
Olha · clinic data analyst
I build the reporting our managers open every morning at a multi-branch medical clinic — and package it so other practices and med spas don't have to start from scratch.
Dollar figures here are labelled by what they are — an association survey (AmSpa), a manufacturer list price (AbbVie's WAC), a market-research model, or a vendor-consultant consensus range — with the scope and year noted. AmSpa's granular revenue-mix and margin figures (including the quoted 27.6% EBITDA) sit behind its paid report and are attributed, not independently verified; the often-cited ~$2M average is AmSpa's own superseded earlier figure, not a current benchmark. Product costs are approximate and volume-dependent. Where a widely-quoted number has no traceable source, we say so rather than repeat it.